Entries by speedbird

Auspherix Appoints Dr. Neil Miller as Chief Scientific Officer

Stevenage, UK, 2 December 2015 – Auspherix Limited (UK), an early stage anti-infectives company, has announced the appointment of Dr. Neil Miller as its Chief Scientific Officer, effective 1 December. As CSO, Dr Miller will take full responsibility for driving forward the Company’s antibiotic R&D programmes, both in house and through partners, into clinical Proof-of-Concept […]

Auspherix and Domainex Expand Collaboration to Develop New Drugs that Tackle Antibiotic-Resistant Bacterial Infections

Cambridge, UK and Stevenage, UK – 15 September 2015 – Domainex and Auspherix today announce an expansion of their collaboration to develop new drugs to tackle the growing threat of resistance to antibiotics. The programme has been extended through to 2017. Since initiating the project in 2014, significant progress has been made towards the invention of new compounds with activity […]

Auspherix Expands Board of Directors and Scientific Advisory Board

Stevenage, UK, 22 July 2015 – Auspherix Limited (UK), an early stage anti-infectives company, has announced that it has expanded and strengthened its Board and Scientific Advisory Board with the appointments of Dr Jared Silverman as Non-Executive Director and Scientific Advisor, and Professor David Livermore as a Scientific Advisor. Dr Silverman’s career has focused on the […]

Auspherix Appoints Experienced Anti-Infectives Clinician to Scientific Advisory Board

Auspherix, an early stage anti-infectives company, today announces that it has expanded its Scientific Advisory Board (SAB) with the appointment of highly experienced clinician, Professor William Hope. William’s career to date has focused on research in antimicrobial pharmacokinetics and pharmacodynamics, mathematic modelling of antimicrobial agents and individualisation of antimicrobial therapy.  He is an NIHR Clinical Scientist […]

Auspherix secures additional AU$1million from MRCF to advance its antibiotic pipeline: Highly experienced team secured

Auspherix secures additional AU$1million from MRCF to advance its antibiotic pipeline Highly experienced team secured Sydney, Australia – Auspherix Pty Ltd, an early stage anti-infectives company developing novel antibiotics to treat resistant bacterial disease has secured a further AU$1 million in a series A financing from Australia’s Medical Research Commercialisation Fund (MRCF), to progress its antibacterial […]

Auspherix and Domainex Announce Collaboration to Develop New Drugs to Treat Antibiotic-resistant Bacterial Infections

Cambridge, UK and Sydney, Australia –  Domainex Ltd. and Auspherix Pty Ltd today announced a collaboration that will progress Auspherix’s novel anti-infective drug discovery programme towards the nomination of a clinical candidate. Auspherix intends to develop much-needed new drugs to fight the increasing problem of antibiotic-resistant bacterial infections, which have been widely reported as one […]

Auspherix Welcomes O’Neill Report on Drug Resistant Infections

Auspherix, an early stage anti-infectives company, today welcomes the O’Neill report on antimicrobial resistance “Tackling Drug-Resistant Infections Globally” which calls for large pharmaceutical companies to participate in the development of new treatments. Research has almost halted in the past 25 years because antibiotics are expensive to develop and provide relatively small returns. Dr Neil Miller, CSO […]

MRCF Invests AU$1m in Antibiotics Start-Up Auspherix

Sydney, Australia – Auspherix Pty Ltd, an early stage anti-infectives company developing novel antibiotics to treat resistant bacterial disease was launched today with AU$1 million in start-up financing from Australia’s Medical Research Commercialisation Fund (MRCF). Auspherix will in-license intellectual property from the ithree institute at the University of Technology Sydney (UTS), emerging from research led by […]